ABSTRACT
Background In vitro drug-screening studies have indicated that camostat mesilate (FOY-305) may prevent SARS-CoV-2 infection into human airway epithelial cells. This study was conducted to investigate whether camostat mesilate is an effective treatment for SARS-CoV-2 infection (COVID-19).
Methods This was a phase 3, multicentre, double-blind, randomised, parallel-group, placebo-controlled study. Patients were enrolled if they were admitted to a hospital within 5 days of onset of COVID-19 symptoms or within 5 days of a positive test for asymptomatic patients. Severe cases (e.g., those requiring oxygenation/ventilation) were excluded. Patients were administered camostat mesilate (600 mg qid; four to eight times higher than the clinical doses in Japan) or placebo for up to 14 days. The primary efficacy endpoint was the time to the first two consecutive negative tests for SARS-CoV-2.
Findings One-hundred and fifty-five patients were randomised to receive camostat mesilate (n=78) or placebo (n=77). The median time to the first test was 11 days in both groups, and conversion to negative status was observed in 60·8% and 63·5% of patients in the camostat mesilate and placebo groups, respectively. The primary (Bayesian) and secondary (frequentist) analyses found no significant differences in the primary endpoint between the two groups. No additional safety concerns beyond those already known for camostat mesilate were identified.
Interpretation Camostat mesilate is no more effective, based on upper airway viral clearance, than placebo for treating patients with mild to moderate SARS-CoV-2 infection with or without symptoms.
Funding Ono Pharmaceutical Co., Ltd.
Evidence before this study SARS-CoV-2 infection (COVID-19), as a significant global health threat, is characterised by broad symptoms and varying disease severity. At the time of planning this study, there were no specific treatments for COVID-19 beyond the use of antiviral drugs, steroids and, in severe cases, ventilation with oxygen. Pre-clinical screening studies revealed the spike (S) protein of SARS-CoV-2 bind to angiotensin converting enzyme II (ACE2) on the host cell membrane. The S protein is then cleaved by a type II transmembrane serine protease (TMPRSS2) as an essential enzyme for the viral entry into host cells. In vitro drug-screening studies have shown that drugs that block binding of the S protein to ACE2 can prevent viral entry into a cell line derived from human airway epithelium. The studies identified 4-(4-guanidinobenzoyloxy)phenylacetic acid, the active metabolite of a serine protease inhibitor (camostat mesilate, FOY-305), as a candidate inhibitor of SARS-CoV-2 entry into humans. A retrospective study of critically ill COVID-19 patients with organ failure revealed a decline in disease activity within 8 days of admission among patients treated with camostat mesilate. In consideration of the preclinical and early clinical evidence, it was hypothesised that camostat mesilate is an effective treatment for patients with COVID-19. Therefore, we planned and executed a phase 3, randomised, double-blind, placebo-controlled study to investigate the efficacy and safety of camostat mesilate for the treatment of patients with mild to moderate COVID-19 infection with or without symptoms. The primary endpoint was the time to the first two consecutive negative tests for SARS-CoV-2. No controlled clinical studies of camostat mesilate had been conducted at the time of planning this study.
Added value of this study The results of this randomised controlled trial revealed that camostat mesilate, administered at a dose of 600 mg qid for up to 14 days, was no more effective than placebo, based on upper airway viral clearance in patients with mild to moderate SARS-CoV-2 infection with or without symptoms. Furthermore, there were no differences between the study groups in terms of other efficacy endpoints. This study used a dose that was four to eight times higher than the clinical doses of camostat mesilate used in Japan for the acute symptoms of chronic pancreatitis and postoperative reflux oesophagitis. The study identified no additional safety concerns beyond those already known for camostat mesilate.
Implications of all available evidence After starting this study, another randomised, placebo-controlled study reported the efficacy and safety of camostat mesilate for the treatment of patients with COVID-19, albeit at a lower dose of 200 mg three times daily. That study also found no difference between camostat mesilate and placebo for the primary endpoint (the time to discharge or a clinical improvement in clinical severity of at least two points on a seven-point ordinal scale). Along with this evidence, our study did not support the use of camostat mesilate as a treatment option for COVID-19. However, since the administration of camostat mesilate was started after the onset of symptoms and presumably the peak viral load, we cannot exclude the possibility that camostat mesilate may be effective if administration is started earlier in the course of infection, or perhaps as prophylactic use in close contacts.
Competing Interest Statement
Taku Kinoshita, Masahiro Shinoda, Katsuya Shiraki, Yuji Hirai, and Kenji Tsushima report institution research funding (in relation to this work) from Ono Pharmaceutical Co., Ltd. in relation to this work.
Yasuhiro Nishizaki reports institution research funding from Ono Pharmaceutical Co., Ltd. in relation to this work; and institution research funding from ITO EN Co., Ltd., AstaReal Co., Ltd., Mizkan Holdings Co., Ltd., and Kanagawa Institute of Industrial Science and Technology unrelated to this work.
Yoshiko Kichikawa reports institution research funding from Ono Pharmaceutical Co., Ltd. in relation to this work; and institution research funding from Nobelpharma Co., Ltd., Chugai Pharmaceutical Co., Ltd., Japan Tobacco Inc., and Pfizer Japan Inc. unrelated to this work.
Masaharu Sinkai reports institution research funding from Ono Pharmaceutical Co., Ltd. in relation to this work; and institutional research funding from FUJIFILM Toyama Chemical Co., Ltd., AstraZeneca K.K, Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc., and Genova Inc. unrelated this work.
Naoyuki Komura and Kazuo Yoshida are employees of Ono Pharmaceutical Co., Ltd.
Yasutoshi Kido reports consultancy fees from Ono Pharmaceutical Co., Ltd. in relation to this work; research funding from Abbott Medical Japan, LLC and ROHTO Pharmaceutical Co., Ltd. unrelated to this work; lecture fees from Abbott Medical Japan, LLC unrelated to this work; equity in Quantum Molecular Diagnostics Japan, LLC unrelated to this work; and reagents for serological testing from Abbott Medical Japan, LLC unrelated to this work.
Hiroshi Kakeya reports consultancy fees from Ono Pharmaceutical Co., Ltd. in relation to this work; and lecture fees from MSD K.K., Pfizer Japan Inc., and Shionogi & Co., Ltd. unrelated to this work.
Naoto Uemura reports consultancy fees from Ono Pharmaceutical Co., Ltd. in relation to this work; and the following activities unrelated to this work: institution research grants from Regeneron Pharma Inc., Eli Lilly Japan K.K., Japan Agency for Medical Research and Development, ARTham Therapeutics Inc., EA Pharma Co., Ltd., VLP Therapeutics, LLC; consultancy fees from Ono Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corp., Sato Pharmaceutical, Co., Ltd., ARTham Therapeutics Inc., Otsuka Pharmaceutical Co., Ltd., EA Pharma Co., Ltd., and Maruho Co., Ltd.; honoraria from Mochida Pharmaceutical Co., Ltd.; fees for participating on advisory boards from Japan Research Foundation Clinical Pharmacology, the Ministry of Education, Culture, Sports, Science and Technology, and the Ministry of Health, Labour and Welfare; fees for leadership or fiduciary roles for American Society for Clinical Pharmacology and Therapeutics and GHIT Fund; unpaid board member for Japanese Society for Clinical Pharmacology and Therapeutics, Clinical Research Support Center Kyushu and Oita IAM; stock or stock options in ARTham Therapeutics Inc. and Oita IAM; and monetary gifts to the institution from Oita IAM.
Junichi Kadota reports consultancy fees from Ono Pharmaceutical Co., Ltd. in relation to this work; and consultancy fees from FUJIFILM Toyama Chemical Co., Ltd., KOBAYASHI Pharma Co., Ltd., and Kyorin Pharma Co., Ltd. unrelated to this work; institutional research funding from MSD Co., Ltd., Taisho Pharma Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Daiichi Sankyo Co., Ltd., Pfizer Japan Inc., Kyorin Pharma Co., Ltd., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Teijin Pharma Ltd. unrelated to this work; and lecture fees from Ono Pharmaceutical Co., Ltd., MSD Co., Ltd., AstraZeneca K.K., Nippon Boehringer Ingelheim Co., Ltd., Pfizer Japan Inc., Shionogi & Co., Ltd., Taisho Toyama Pharma Co., Ltd., Meiji Seika Pharma Co., Ltd., Sanofi K.K., Kyorin Pharma Co., Ltd., Astellas Pharma Inc., Sumitomo Dainippon Pharma Co., Ltd., Bristol-Myers Squibb Company, Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Novartis Pharma K.K., Taisho Pharma Co., Ltd., FUJIFILM Medical Co., Ltd., GlaxoSmithKline K.K., and DENKA SEIKEN Co., Ltd. unrelated to this work.
Clinical Trial
NCT04657497 jRCT2031200198
Funding Statement
This study was funded by Ono Pharmaceutical Co., Ltd.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The protocol and patient consent forms were reviewed and approved by the following institutional review boards or ethics committees at each participating centre: Haradoi Hospital Institutional Review Board, Higashiosaka City Medical Center Institutional Review Board, Institutional Review Board of Tokyo Medical University Hachioji Medical Center, International University of Health and Welfare Institutional Review Board, Juntendo University Hospital Institutional Review Board, Kantorosai Hospital Institutional Review Board, Kobori Central Clinical Research Ethics Committee, Koseiren Hospital Central Institutional Review Board, Mishuku Hospital Institutional Review Board, National Hospital Organization Kanazawa Medical Center Institutional Review Board, Nihon University Hospitals' Joint Institutional Review Board, Okayama City Hospital Institutional Review Board, Review Board of Human Rights and Ethics for Clinical Studies Institutional Review Board, Review Board of Human Rights and Ethics for Clinical Studies Institutional Review Board, Saiseikai Kurihashi Hospital Institutional Review Board, Saitama Medical Center Institutional Review Board, Saitama Prefectural Cardiovascular and Respiratory Center Institutional Review Board, Tachikawa Hospital Institutional Review Board, Tokai University Hospital Group Institutional Review Board, Tokushukai Group Institutional Review Board, Tokyo Medical and Dental University Hospital Institutional Review Board, Tokyo Metropolitan Hiroo Hospital Institutional Review Board, Tokyo Shinagawa Hospital Institutional Review Board, Yokohama Municipal Citizen's Hospital Institutional Review Board, and Yokosuka Kyosai Hospital Institutional Review Board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Prior publication None.
Data Availability
Qualified researchers may request Ono Pharma to disclose individual patient-level data from clinical studies through the following website: https://www.clinicalstudydatarequest.com/. For more information on Ono Pharma’s Policy for the Disclosure of Clinical Study Data, please see the following website: https://www.ono.co.jp/eng/rd/policy.html.
